READlogoJDRF
This website can be best seen with Internet Explorer 7 or higher, Mozilla Firefox 2.0 or higher

Ranibizumab for Edema of the mAcula in Diabetes:
Protocol 3 with High Dose -
the READ 3 Study

 

The goal of the READ-3 Study, a large multi-center clinical trial conducted across the United States, is to investigate the safety, tolerability, and bioactivity of two different doses (0.5mg and 2.0mg) of ranibizumab, a monoclonal antibody against VEGF, in eyes with diabetic macular edema.

The READ-3 Study is sponsored by the Juvenile Diabetes Research Foundation. The study drug, ranibizumab, is provided by Genentech, Inc.